English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17773/20058 (89%)
Visitors : 8865024      Online Users : 620
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31767

    標題: Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways
    作者: Chen, Yi-Jin
    Wan, Wen-Hung
    Wu, Wan-Yu
    Hsu, Chia-Chi
    Wei, Ling-Rung
    Wang, Sheng-Fan
    Hsu, Ya-Wen
    Liaw, Chih-Chuang
    Tsai, Wan-Chi
    貢獻者: Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol
    Cathay Gen Hosp, Dept Otolaryngol
    SijhihCathay Gen Hosp, Dept Otolaryngol
    FuJen Catholic Univ, Sch Med
    Kaohsiung Med Univ, Ctr Infect Dis & Canc Res
    Chia Nan Univ Pharm Sci, Dept Hosp & Hlth Care Adm
    Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol
    Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources
    Kaohsiung Med Univ Hosp, Dept Lab Med
    關鍵字: Acetyl-L-Cysteine
    Hydroxamic Acid Saha
    Human Leukemia-Cells
    日期: 2017-08-22
    上傳時間: 2018-11-30 15:55:57 (UTC+8)
    出版者: Public Library Science
    摘要: Objective Pancreatic cancer is one of the most lethal types of cancer with a 5-year survival rate of similar to 5%. Histone deacetylases (HDACs) participate in many cellular processes, including carcinogenesis, and pharmacological inhibition of HDACs has emerged as a potential therapeutic strategy. In this study, we explored antitumor activity of the novel HDAC inhibitor AR-42 in pancreatic cancer. Methods Human pancreatic cancer cell lines BxPC-3 and PANC-1 were used in this study. Real-time PCR, RT-PCR, and western blotting were employed to investigate expression of specific genes and proteins, respectively. Translocation of apoptosis-inducing factor was investigated by immunofluorescence and subcellular fractionation. The number of apoptotic cells, cell cycle stages, and reactive oxygen species (ROS) generation levels were determined by flow cytometry. Cell invasiveness was examined by the Matrigel invasion assay. Efficacy of AR-42 in vivo was evaluated by utilizing BxPC-3 xenograft mouse model. Results AR-42 inhibited pancreatic cancer cell proliferation by causing G2/M cell cycle arrest via regulating expression levels of genes and proteins involved in cell cycle. AR-42 also induced ROS generation and DNA damage, triggering apoptosis of pancreatic cancer cells via both caspase-3-dependent and caspase-3-independent pathways. In addition, AR-42 increased expression levels of negative regulators of p53 (miR-125b, miR-30d, and miR33), which could contribute to lower expression level of mutant p53 in pancreatic cancer cells. Cell invasion assay showed that AR-42 reduced cancer cell aggressiveness and significantly diminished BxPC-3 xenograft tumor growth in vivo. Conclusion AR-42, a novel HDAC inhibitor, inhibited pancreatic cancer cells by regulating p53 expression, inducing cell cycle arrest, particularly at the G2/M stage, and activating multiple apoptosis pathways. Additionally, AR-42 inhibited cell invasiveness and potently suppressed pancreatic cancer tumors in vivo. We conclude that by virtue of its multiple mechanisms of action, AR-42 possesses a considerable potential as an antitumor agent in pancreatic cancer.
    關聯: Plos One, v.12, n.8, e0183368
    Appears in Collections:[醫務管理系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1371-journal.pone.0183368.pdf1821KbAdobe PDF68View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback